Observational studyJournal of comparative effectiveness research2023

Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA.

Lita Araujo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.